6GV0 image
Deposition Date 2018-06-20
Release Date 2019-07-03
Last Version Date 2024-11-06
Entry Detail
PDB ID:
6GV0
Keywords:
Title:
Insulin glulisine
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.26 Å
R-Value Free:
0.15
R-Value Work:
0.12
R-Value Observed:
0.12
Space Group:
H 3
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Insulin
Gene (Uniprot):INS
Chain IDs:B, D
Chain Length:30
Number of Molecules:2
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Insulin
Gene (Uniprot):INS
Chain IDs:A (auth: G), C (auth: I)
Chain Length:21
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Analysis of insulin glulisine at the molecular level by X-ray crystallography and biophysical techniques.
Sci Rep 11 1737 1737 (2021)
PMID: 33462295 DOI: 10.1038/s41598-021-81251-2

Abstact

This study concerns glulisine, a rapid-acting insulin analogue that plays a fundamental role in diabetes management. We have applied a combination of methods namely X-ray crystallography, and biophysical characterisation to provide a detailed insight into the structure and function of glulisine. X-ray data provided structural information to a resolution of 1.26 Å. Crystals belonged to the H3 space group with hexagonal (centred trigonal) cell dimensions a = b = 82.44 and c = 33.65 Å with two molecules in the asymmetric unit. A unique position of D21Glu, not present in other fast-acting analogues, pointing inwards rather than to the outside surface was observed. This reduces interactions with neighbouring molecules thereby increasing preference of the dimer form. Sedimentation velocity/equilibrium studies revealed a trinary system of dimers and hexamers/dihexamers in dynamic equilibrium. This new information may lead to better understanding of the pharmacokinetic and pharmacodynamic behaviour of glulisine which might aid in improving formulation regarding its fast-acting role and reducing side effects of this drug.

Legend

Protein

Chemical

Disease

Primary Citation of related structures